Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation

Background and study aims: Patients with cirrhosis who undergo endoscopy under sedation could be at increased risk of complications. We assessed the utility of the critical flicker frequency (CFF) in the recovery of cognitive function.

Patients and methods: This was a prospective study in patients with cirrhosis who underwent endoscopy under sedation with propofol in a tertiary care center. The main outcome was deterioration in cognitive function as measured by the number connection test A and B (NCT-A, -B), digit symbol test (DST), serial dotting test (SDT), and line tracing test (LTT) before and 2 h after endoscopy. CFF was recorded before and then every 30 min after endoscopy for the next 2 h.

Results: In the 108 patients there was no deterioration in results of the psychometric tests after the endoscopy (NCT-A 65.2 ± 44.4 vs. 62.4 ± 43.6 s, P = 0.01; NCT-B 110.4 ± 34.7 vs. 109.6 ± 44.6 s, P = 0.45; DST 26.2 ±1 0.0 vs. 26.7 ± 9.9, P = 0.25; SDT 88.6 ± 47.5 vs. 84.3 ± 44.1 s, P = 0.02; LTT 116.6 ± 55.2 vs. 115.4 ± 51.3 s, P = 0.47.) Patients with minimal hepatic encephalopathy (MHE; n = 64) did not show any deterioration in cognitive function at 2 h (NCT-A 87.7 ± 45.4 vs. 84.3 ± 44.9 s, P = 0.06; NCT-B 134.8 ± 65.4 vs. 132.7 ± 58.8 s, P = 0.46; DST 21.4 ± 8.9 vs. 22.2 ± 8.8, P = 0.09; SDT 107.1 ± 53.0 vs. 102.7 ± 48.5 s, P = 0.03; and LTT 131.5 ± 62.2 vs. 129.6 ± 57.2 s, P = 0.46). There was a significant difference between CFF at baseline and at 30 min and 1 h but no difference thereafter in non-MHE patients, MHE patients, and in controls. A total of 30 patients (28 %) had CFF < 38 Hz. In these patients, CFF at 2 h did not significantly differ from baseline CFF (35.9 ± 1.5 vs. 36.1 ± 2.0 Hz; P = 0.19). A total of 10 patients (9 %) had transient hypoxemia and 18 (17 %) had hypotension during the procedure. The endoscopy was completed in all patients.

Conclusions: Propofol is safe in patients with cirrhosis and the CFF is a useful tool for the assessment of recovery from sedation in these patients.

References

• 1 Grace N D, Groszmann R J, Garcia-Tsao G et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium.  Hepatology. 1998;  28 868-880
• 2 Benjamin S B. Complications of conscious sedation.  Gastrointest Endosc Clin North Am. 1996;  6 277-286
• 3 Assy N, Rosser B G, Grahame G R, Minuk G Y. Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy.  Gastrointest Endosc. 1999;  49 690-694
• 4 Vasudevan A E, Goh K L, Bulgiba A M. Impairment of psychomotor responses after conscious sedation in cirrhotic patients undergoing therapeutic upper GI endoscopy.  Am J Gastroenterol. 2002;  97 1717-1721
• 5 Rinetti M, Ascalone V, Colombi Z inelli et al. A pharmacokinetic study on midazolam in compensated liver cirrhosis.  Int J Clin Pharmacol Res. 1985;  5 405-411
• 6 Servin F, Cockshott I D, Farinotti R et al. Pharmacokinetics of propofol infusions in patients with cirrhosis.  Br J Anaesth. 1990;  65 177-183
• 7 MacGilchrist A J, Birnie G G, Cook A et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.  Gut. 1986;  27 190-195
• 8 Riphaus A, Lechowicz I, Frenz M B et al. Propofol sedation for upper gastrointestinal endoscopy in patients with liver cirrhosis as an alternative to midazolam to avoid acute deterioration of minimal encephalopathy: a randomized, controlled study.  Scand J Gastroenterol. 2009;  44 1244-1251
• 9 Amorós A, Aparicio J R, Garmendia M et al. Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy.  Gastrointest Endosc. 2009;  70 262-268
• 10 Ortiz M, Jacas C, Córdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations.  J Hepatol. 2005;  42 Suppl 1 S45-53
• 11 Romero-Gomez M, Cordoba J, Jover R et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.  Hepatology. 2007;  45 879-885
• 12 Kircheis G, Wettstein M, Timmermann L et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy.  Hepatology. 2002;  35 357-366
• 13 Sharma P, Sharma B C, Sarin S K. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis.  Hepatobiliary Pancreat Dis Int. 2010;  9 27-32
• 14 Sharma P, Sharma B C, Puri V et al. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy.  J Hepatol. 2007;  47 67-73
• 15 Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998.  Hepatology. 2002;  35 716-721
• 16 Cohen L B, Delegge M H, Aisenberg J et al. AGA Institute review of endoscopic sedation.  Gastroenterology. 2007;  133 675-701
• 17 Darwin P, Zangara J, Heller T et al. Unsedated esophagoscopy for the diagnosis of esophageal varices in patients with cirrhosis.  Endoscopy. 2001;  32 971-973
• 18 Mosca S, Balzano A. Is routine topical anesthesia or conscious sedation necessary in upper endoscopy, especially in patients with liver cirrhosis?.  Endoscopy. 2001;  33 639-640
• 19 Romero-Gomez M, Boza F, Garcia-Valdecasas M S et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.  Am J Gastroenterol. 2001;  96 2718-2723
• 20 Das A, Dhiman R K, Saraswat V A et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.  J Gastroenterol Hepatol. 2001;  16 531-535
• 21 Hartmann I J, Groeneweg M, Quero J C et al. The prognostic significance of subclinical hepatic encephalopathy.  Am J Gastroenterol. 2000;  95 2029-2034
• 22 Watanabe A, Sakai T, Sato S et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.  Hepatology. 1997;  26 1410-1414
• 23 Sharma P, Sharma B C, Puri V et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.  Eur J Gastroenterol Hepatol. 2008;  20 506-511
• 24 Prasad S, Dhiman R K, Duseja A et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.  Hepatology. 2007;  45 549-559
• 25 Bajaj J S, Wade J B, Sanyal A J. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy.  Hepatology. 2009;  50 2014-2021
• 26 Thuluvath P J. Toward safer sedation in patients with cirrhosis: have we done enough?.  Gastrointest Endosc. 2009;  70 269-271
• 27 Lichtenstein D R, Jagannath S Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy et al. Sedation and anesthesia in GI endoscopy.  Gastrointest Endosc. 2008;  68 815-826
• 28 Mackenzie N, Grant I S. Propofol for intravenous sedation.  Anaesthesia. 1987;  42 3-6
• 29 Morcos W E, Payne J P. The induction of anaesthesia with propofol compared in normal and renal failure patients.  Postgrad Med J. 1985;  61 62-63